Rein Therapeutics (RNTX) Long-Term Debt Issuances (2018 - 2026)
Rein Therapeutics (RNTX) posted quarterly Long-Term Debt Issuances of $4.3 million for Q1 2026, up 143233.33% quarter-over-quarter from $3000.0 in Q4 2020.
Rein Therapeutics (RNTX) Long-Term Debt Issuances (2018 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Long-Term Debt Issuances for 3 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 239.89% YoY), while the FY2020 annual figure was $387000.0, changed N/A from the prior year.
- Long-Term Debt Issuances grew to $4.3 million in Q1 2026 per RNTX's latest filing, from $3000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $4.3 million in Q1 2026 and bottomed at $4.3 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.08 Mn |
| Jun 30, 2026 | 1.08 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2020 | 3,000.00 |
| Dec 31, 2020 | 3,000.00 |
| Dec 31, 2018 | 1.26 Mn |
| Dec 31, 2018 | 1.26 Mn |